{
    "id": 31478,
    "fullName": "EGFR L862V",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "EGFR L862V lies within the protein kinase domain of the Egfr protein (UniProt.org). L862V has been identified in the scientific literature (PMID: 21841502), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Nov 2019).",
            "references": [
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 16690,
                    "pubMedId": 21841502,
                    "title": "Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21841502"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 1956,
        "geneSymbol": "EGFR",
        "terms": [
            "EGFR",
            "ERBB",
            "ERBB1",
            "HER1",
            "mENA",
            "NISBD2",
            "PIG61"
        ]
    },
    "variant": "L862V",
    "createDate": "11/05/2019",
    "updateDate": "11/05/2019",
    "referenceTranscriptCoordinates": {
        "id": 185268,
        "transcript": "NM_005228",
        "gDna": "chr7:g.55191833C>G",
        "cDna": "c.2584C>G",
        "protein": "p.L862V",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 19062,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Iressa (gefitinib) treatment resulted in disease progression after 2 months of treatment in a patient with metastatic lung adenocarcinoma harboring EGFR L862V (PMID: 21841502).",
            "molecularProfile": {
                "id": 33830,
                "profileName": "EGFR L862V"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 16690,
                    "pubMedId": 21841502,
                    "title": "Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21841502"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 33830,
            "profileName": "EGFR L862V",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 185268,
            "transcript": "NM_005228",
            "gDna": "chr7:g.55191833C>G",
            "cDna": "c.2584C>G",
            "protein": "p.L862V",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}